Slide 1

GUSTAVE ROUSSY

THÈME DU DIAPORAMA



Dose

escalation

for advanced disease in HR CTV



Dose

de-escalation

for limited and favourable

advanced disease (good response,…)



Testing Dose/Volume

constraints and

morbidity/QoL



Concomitant ERT-CT and

adjuvant chemotherapy

for

subgroups with high risk of

distant metastases



Biomarker investigation

(Hypoxia, HPV, EGFR, VEGF..)

Future research

In EMBRACE II, the improved therapeutic window (through increased application

715

and/or OAR dose de-escalation (figure 4.1). In tumours with large residual CTV

716

the potential to improve local control significantly. In limited size CTV

volumes

717

escalation has minor impact on local control while it has potential to reduce m

718

application of the IC/IS technique in at least 20% of the patients in each institution

719

distribution of ~20% IB, ~50% IIB, ~20% IIIB and ~10% others. If a given patient p

720

limited or extensive disease, the threshold of 20% IC/IS applications must be adapt

721

Figure 4.1 Principles for dose de-escalation and dose escalation in EMBRACE II. Th

722